Literature DB >> 21768451

It is time to include patients with brain tumors in phase I trials in oncology.

Patrick Y Wen1, David Schiff, Timothy F Cloughesy, David A Reardon, Tracy T Batchelor, Bruce A Chabner, Keith Flaherty, John F de Groot, Mark R Gilbert, Evanthia Galanis, Susan M Chang, Gary K Schwartz, David Peereboom, Minesh P Mehta, W K Alfred Yung, Stuart A Grossman, Michael D Prados, Lisa M DeAngelis.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21768451      PMCID: PMC4836609          DOI: 10.1200/JCO.2011.36.6328

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  13 in total

1.  Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Authors:  Tracy T Batchelor; Dan G Duda; Emmanuelle di Tomaso; Marek Ancukiewicz; Scott R Plotkin; Elizabeth Gerstner; April F Eichler; Jan Drappatz; Fred H Hochberg; Thomas Benner; David N Louis; Kenneth S Cohen; Houng Chea; Alexis Exarhopoulos; Jay S Loeffler; Marsha A Moses; Percy Ivy; A Gregory Sorensen; Patrick Y Wen; Rakesh K Jain
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

3.  Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia L Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa M DeAngelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard Kaplan; Anthony J Murgo; Charles Stiles; Michael D Prados
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

4.  Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium.

Authors:  M R Fetell; S A Grossman; J D Fisher; B Erlanger; E Rowinsky; J Stockel; S Piantadosi
Journal:  J Clin Oncol       Date:  1997-09       Impact factor: 44.544

5.  A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.

Authors:  Jeffrey J Raizer; Lauren E Abrey; Andrew B Lassman; Susan M Chang; Kathleen R Lamborn; John G Kuhn; W K Alfred Yung; Mark R Gilbert; Kenneth D Aldape; Patrick Y Wen; Howard A Fine; Minesh Mehta; Lisa M Deangelis; Frank Lieberman; Timothy F Cloughesy; H Ian Robins; Janet Dancey; Michael D Prados
Journal:  Neuro Oncol       Date:  2009-12-14       Impact factor: 12.300

6.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

7.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

8.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

9.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways.

Authors: 
Journal:  Nature       Date:  2008-09-04       Impact factor: 49.962

10.  Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Authors:  E S Newlands; G R Blackledge; J A Slack; G J Rustin; D B Smith; N S Stuart; C P Quarterman; R Hoffman; M F Stevens; M H Brampton
Journal:  Br J Cancer       Date:  1992-02       Impact factor: 7.640

View more
  9 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

Review 2.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

3.  Clinical trial design in brain metastasis: approaches for a unique patient population.

Authors:  David M Peereboom
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

4.  Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Authors:  Mrinal M Gounder; Lakshmi Nayak; Solmaz Sahebjam; Alona Muzikansky; Armando J Sanchez; Serena Desideri; Xiaobu Ye; S Percy Ivy; L Burt Nabors; Michael Prados; Stuart Grossman; Lisa M DeAngelis; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

5.  Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.

Authors:  Eudocia Q Lee; Michael Weller; Joohee Sul; Stephen J Bagley; Solmaz Sahebjam; Martin van den Bent; Manmeet Ahluwalia; Jian L Campian; Evanthia Galanis; Mark R Gilbert; Matthias Holdhoff; Glenn J Lesser; Frank S Lieberman; Minesh P Mehta; Marta Penas-Prado; Karisa C Schreck; Roy E Strowd; Michael A Vogelbaum; Tobias Walbert; Susan M Chang; L Burt Nabors; Stuart Grossman; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

Review 6.  Combination of Radiotherapy and Targeted Agents in Brain Metastasis: An Update.

Authors:  Zarmeneh Aly; David M Peereboom
Journal:  Curr Treat Options Neurol       Date:  2016-07       Impact factor: 3.598

Review 7.  Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?

Authors:  Shota Tanaka; David N Louis; William T Curry; Tracy T Batchelor; Jorg Dietrich
Journal:  Nat Rev Clin Oncol       Date:  2012-11-27       Impact factor: 66.675

8.  Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Authors:  Niamh Coleman; Vasiliki Michalarea; Scheryll Alken; Karim Rihawi; Raquel Perez Lopez; Nina Tunariu; Ann Petruckevitch; L R Molife; Udai Banerji; Johann S De Bono; Liam Welsh; Frank Saran; Juanita Lopez
Journal:  J Neurooncol       Date:  2018-04-10       Impact factor: 4.130

Review 9.  The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Jeffrey J Olson; Lakshmi Nayak; D Ryan Ormond; Patrick Y Wen; Steven N Kalkanis
Journal:  J Neurooncol       Date:  2014-04-17       Impact factor: 4.130

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.